ストックスクリーナーアプリを入手
3.79
3.84%
0.14
アフターアワーズ：
3.79
前日終値:
$3.65
開ける：
$3.6407
24時間の取引高:
7,835
Relative Volume:
0.01
時価総額：
$16.16M
収益：
-
当期純損益:
$-60.61M
株価収益率:
-4.2111
EPS:
-0.9
ネットキャッシュフロー:
$-22.91M
1週間 パフォーマンス:
+1.34%
1か月 パフォーマンス:
-8.23%
6か月 パフォーマンス:
+14.33%
1年 パフォーマンス:
+491.45%
1日の値動き範囲:
$3.5832
$3.79
1週間の範囲:
$3.46
$3.88
52週間の値動き範囲:
$0.0815
$7.7699
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
BLRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BLRX
Bioline Rx Ltd Adr
|
3.79 | 15.56M | 0 | -60.61M | -22.91M | -0.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2017-05-18 | アップグレード | Maxim Group | Hold → Buy |
| 2017-02-13 | 開始されました | Rodman & Renshaw | Buy |
| 2016-08-12 | ダウングレード | Maxim Group | Buy → Hold |
| 2015-08-17 | 繰り返されました | Maxim Group | Buy |
| 2015-07-27 | 繰り返されました | ROTH Capital | Buy |
| 2015-06-22 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Bioline Rx Ltd Adr (BLRX) 最新ニュース
Earnings call transcript: BioLineRx Q2 2025 sees restructuring and innovation - Investing.com
BioLineRx: Strategic Pipeline Expansion and Strong Financial Health Justify Buy Rating - TipRanks
BioLineRx Ltd. Reports Q2 2025 Financial Results - TipRanks
BioLineRx Reports Q2 2025 Financials and Strategic Updates - MSN
BioLineRx To Report Second Quarter 2025 Results On August 14, 2025 - Barchart.com
BioLineRx: Promising Financial Position and Strategic Initiatives Drive Buy Rating - TipRanks
BioLineRx Reports Second Quarter 2025 Financial Results And Provides Corporate Update - Barchart.com
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
BioLineRx Ltd. Approves Key Proposals at Annual Meeting - TipRanks
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Capricor Therapeutics (CAPR) and Abbott Laboratories (ABT) - The Globe and Mail
Promising Phase 2 Trial Results Drive Buy Rating for BioLine RX in mPDAC Treatment - TipRanks
BioLineRx ADR: Positive Earnings Call Highlights and Challenges - MSN
Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
BioLineRx upgraded to Buy from Hold at JonesResearch - Yahoo Finance
BioLineRx reports promising pancreatic cancer trial data By Investing.com - Investing.com South Africa
BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating By Stocktwits - Investing.com India
BioLineRx announces new data from Phase 2 combination trial of motixafortide - TipRanks
Jones Trading raises BioLineRx stock rating, targets $12 By Investing.com - Investing.com South Africa
Jones Trading raises BioLineRx stock rating, targets $12 - Investing.com India
BioLineRx Presents Promising Phase 2 Data at ASCO 2025 for Pancreatic Cancer Trial - TipRanks
BioLineRx reports promising pancreatic cancer trial data - Investing.com
JonesTrading Reaffirms Their Hold Rating on Bioline RX Ltd Sponsored ADR (BLRX) - The Globe and Mail
Jones Trading maintains Hold on BioLineRx stock amid royalty prospects - Investing.com India
Jones Trading maintains Hold on BioLineRx stock amid royalty prospects By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock - Investing.com
H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock By Investing.com - Investing.com South Africa
BioLineRx: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks
BioLineRx Ltd. Reports Q1 2025 Financial Results - TipRanks
BioLineRx Q1 Earnings Rise Despite Fall In Revenue: Retail Stays Super Confident By Stocktwits - Investing.com India
BioLineRx Reports Q1 2025 Financial Results and Strategic Updates - TipRanks
Options Volatility and Implied Earnings Moves Today, May 27, 2025 - TipRanks
BioLineRx Ltd. Schedules Annual Shareholder Meeting for June 2025 - TipRanks
Analysts’ Top Healthcare Picks: Bicara Therapeutics Inc. (BCAX), Fulcrum Therapeutics (FULC) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and CVRx (CVRX) - The Globe and Mail
BioLineRx stock rating cut to Hold at Jones Trading - Investing.com
BLRX stock touches 52-week low at $2.85 amid sharp annual decline - Investing.com
H.C. Wainwright raises BioLineRx stock target to $26 - Investing.com India
BioLineRx Ltd. Reports 2024 Financial Results and Strategic Progress - TipRanks
BioLineRx Earnings Call: Strategic Shifts and Growth - TipRanks
BioLineRx price target adjusted to $26 at H.C. Wainwright after reverse split - TipRanks
Options Volatility and Implied Earnings Moves This Week, March 31 – April 03, 2025 - The Globe and Mail
BioLineRx Reports Strong 2024 Financial Results and Strategic Advancements - TipRanks
Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire
Investor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire
BioLineRx stock hits 52-week low at $3.24 amid sharp decline - Investing.com
BioLineRx announces strategic shift with licensing deals - Investing.com
BioLineRx Announces 1:40 ADS Ratio Change, Confirms $29.5M Cash Runway Through 2026 - Stock Titan
BioLineRx stock touches 52-week low at $0.14 amid downturn - Investing.com
BiolineRx Announces Major Direct Offering to Bolster Operations - TipRanks
Bioline Rx Ltd Adr (BLRX) 財務データ
収益
当期純利益
現金流量
EPS
0.96%
1.09%
大文字化:
|
ボリューム (24 時間):